In vivo therapeutic administration of miR-34a and PTX through systemic delivery also led to delayed tumor growth in a B16F10-CD44+ tumor model by inhibiting CD44 and inducing apoptosis in B16F10-CD44+ cells [148]. This evidence concerns the gene CD44 and neoplasm.